Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CencoraCOR +3.57%73 EV-to-OCF is 14.69 as of Aug. 06, 2026, which is 23% above its 10-year median of 11.93. GuruFocus rates COR with a GF Score™ of 73/100 and a GF Value™ of $300.38 (Fairly Valued). The stock has 2 warning signs investors should review. Among 118 Medical Distribution companies, Cencora ranks worse than 71.19% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Cencora's Enterprise Value is $70,814 Mil.
Cencora's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $4,821 Mil. Therefore, Cencora's EV-to-OCF for today is 14.69.
The historical rank and industry rank for Cencora's EV-to-OCF or its related term are showing as below:
COR'
s EV-to-OCF Range Over the Past 10 Years
Min: -492.87 Med: 11.93 Max: 37.99
Current: 14.69
During the past 13 years, the highest EV-to-OCF of Cencora was 37.99. The lowest was -492.87. And the median was 11.93.
COR's EV-to-OCF is ranked worse than 71.19% of 118
companies
in the Medical Distribution industry
Industry Median: 7.535
vs COR: 14.69
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cencora's share price for today is $317.22.
Cencora's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $9.520.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Cencora EV-to-OCF Related Terms
Cencora EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Cencora's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Cencora's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cencora EV-to-OCF vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Cencora's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Cencora's EV-to-OCF falls into.
Cencora's current Enterprise Value is $70,814 Mil.
Cencora's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $4,821 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cencora (COR) has a EV-to-OCF of 14.69 as of Aug. 06, 2026. This is 23% above median its historical median of 11.93. According to the industry distribution chart, Cencora ranks #84 out of 118 companies in the Medical Distribution industry, placing it in the top 71.2%.
Is Cencora's EV-to-OCF too high?
Cencora's current EV-to-OCF of 14.69 is 23% above median its 10-year median of 11.93. The Medical Distribution industry median EV-to-OCF is 7.54. Cencora's value of 14.69 is 95% above this industry median. Based on the distribution chart, Cencora ranks #84 out of 118 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Cencora has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cencora's EV-to-OCF compare to CAH and MCK?
According to the Medical Distribution industry distribution chart, Cencora ranks #84 out of 118 companies for EV-to-OCF. This places Cencora in the lower half of its industry. The industry median EV-to-OCF is 7.54. Cencora's value of 14.69 is 95% above this benchmark. While the company's 10-year median is 11.93 vs. the industry median of 7.54, Cencora has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Distribution company?
The median EV-to-OCF among Medical Distribution companies is 7.54, based on 118 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cencora's current EV-to-OCF of 14.69 is 95% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Distribution industry, the median EV-to-OCF is 7.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cencora's current EV-to-OCF is 14.69, which is 23% above median its own 10-year median of 11.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cencora stock overvalued right now?
Based on GuruFocus' analysis, Cencora (COR) is currently considered Fairly Valued. The stock's GF Value™ is $300.38, compared to a current price of $317.22 — trading 5.6% above its estimated fair value. The current EV-to-OCF is 14.69, which is 23% above median its 10-year median of 11.93 and 95% above the Medical Distribution industry median of 7.54. Cencora's overall GF Score™ is 73/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Cencora (COR), the current EV-to-OCF is 14.69 as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cencora (COR) Overvalued in 2026?
Based on GuruFocus' analysis, Cencora stock appears to be overvalued.
The current stock price of $317.22 is trading 5.6% above its estimated GF Value™ of $300.38.
GuruFocus considers Cencora to be Fairly Valued.
Key valuation signals for COR:
EV-to-OCF: 14.69 (23% above median its 10-year median of 11.93)
GF Value™: $300.38 vs. price of $317.22 (5.6% above fair value)
Industry Position: 95% above the Medical Distribution median (#84 of 118)
No single metric tells the full story. See the COR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health hold over 90% share of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
73GF Score
Get the complete analysis for COR
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COR has been successfully added to your 
